Literature DB >> 8621901

Specific regulation of VLA-4 and alpha 4 beta 7 integrin expression on human activated T lymphocytes.

T Hernández-Caselles1, M Martínez-Esparza, A I Lazarovits, P Aparicio.   

Abstract

Modulation of VLA integrins was studied in several human T cell clones upon specific and nonspecific cellular activation. Human activated T lymphocytes down-regulated both alpha 4 beta 1 and alpha 4 beta 7 integrins upon specific recognition of alloantigens (cytotoxic T cells) or in the presence of Staphylococcus enterotoxin B (superantigen recognizing noncytotoxic T cells). In contrast, the expression of other membrane integrins, such as VLA-1 and VLA-5 integrins, was not modified. Down-regulation of alpha 4 beta 1 and alpha 4 beta 7 integrins was observed as early as 3 h after stimulation, lasted later than 72 h and was partially inhibited by cytochalasin D. Interestingly, neither target cells nor NK cells modulated CD49d expression after interaction with T cells of K562, respectively, suggesting that CD49d expression was linked to specific T cell activation. The down-regulation of the CD49d chain in T cell clones stimulated with immobilized anti-CD3 mAbs confirmed the role of TCR-mediated activation in CD49d regulation. However, the CD3-independent cellular aggregation induced by soluble anti-CD43 mAb was also able to strongly down-regulate alpha 4 beta 1 and alpha 4 beta 7. The present work shows the first evidence that CD49d subunit-bearing integrin expression is distinctly regulated from other integrins after Ag or superantigen recognition by human activated T cells. CD49d modulation may be relevant for the traffic and tissue localization of locally activated T cells during immune responses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621901

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine.

Authors:  Elisha Waldman; Sydney X Lu; Vanessa M Hubbard; Adam A Kochman; Jeffrey M Eng; Theis H Terwey; Stephanie J Muriglan; Theo D Kim; Glenn Heller; George F Murphy; Chen Liu; Onder Alpdogan; Marcel R M van den Brink
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

2.  Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation.

Authors:  J Meenan; J Spaans; T A Grool; S T Pals; G N Tytgat; S J van Deventer
Journal:  Gut       Date:  1997-02       Impact factor: 23.059

3.  A distinct cellular profile is seen in the human endocervix during Chlamydia trachomatis infection.

Authors:  Mercedes Ficarra; Joyce S A Ibana; Constance Poretta; Liang Ma; Leann Myers; Stephanie N Taylor; Sheila Greene; Barbara Smith; Michael Hagensee; David H Martin; Alison J Quayle
Journal:  Am J Reprod Immunol       Date:  2008-11       Impact factor: 3.886

4.  Repeated stimulation of CD4 effector T cells can limit their protective function.

Authors:  Dawn M Jelley-Gibbs; John P Dibble; Svetlana Filipson; Laura Haynes; Roslyn A Kemp; Susan L Swain
Journal:  J Exp Med       Date:  2005-03-28       Impact factor: 14.307

5.  Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration.

Authors:  Kazutoshi Aoyama; Asim Saha; Jakub Tolar; Megan J Riddle; Rachelle G Veenstra; Patricia A Taylor; Rune Blomhoff; Angela Panoskaltsis-Mortari; Christopher A Klebanoff; Gérard Socié; David H Munn; William J Murphy; Jonathan S Serody; Leshara M Fulton; Takanori Teshima; Roshantha A Chandraratna; Ethan Dmitrovsky; Yanxia Guo; Randolph J Noelle; Bruce R Blazar
Journal:  Blood       Date:  2013-06-27       Impact factor: 22.113

6.  The functional paradox of CD43 in leukocyte recruitment: a study using CD43-deficient mice.

Authors:  R C Woodman; B Johnston; M J Hickey; D Teoh; P Reinhardt; B Y Poon; P Kubes
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.